Company intelligence / Profile preview

Lizhu

Guangdong, China

Ownership: Private
Employees: ~8000
Development stage: Other

Overview

Lizhu is a top Chinese pharmaceutical group with commercialized portfolios in small molecule, biologic, and recombinant protein drugs, including innovative and generic agents in digestive, cardiovascular, reproductive, and neurological areas.[1][5][9] Notable recent clinical achievements include successful product approvals in digestive therapeutics and ongoing expansion into new indications such as venous thromboembolism prevention.[3][7]

Therapeutic areas: EndocrinologyGastroenterologyCardiovascularOtherOncologyNeurology
Modalities: Small moleculeSynthetic peptideMonoclonal antibodyBiologicRecombinant protein
Industry: Biotech

Partnerships

Nanjing Vcare PharmaTechShanghai Huahuituo Pharmaceutical Technology

Beyond the preview

Go deeper on Lizhu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lizhu.

Explore the full profile